<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE254nnn/GSE254341/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Methylation profiling</omics_type><species> Mus musculus</species><species>Homo sapiens</species><gds_type>Methylation profiling by high throughput sequencing</gds_type><gds_type> Genome binding/occupancy profiling by high throughput sequencing</gds_type><gds_type> Expression profiling by high throughput sequencing</gds_type><gds_type> Other</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254341</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Targeting Nat10 reprograms regulatory T cells function to enhance anti-PD-1 immunotherapy sensitivity in lung cancer</name><description>A significant challenge for improving the efficacy of immune checkpoint blockade (ICB) therapy is the concurrent activation of regulatory T (Treg) cells, which can dampen anti-tumor responses. Thus, elucidating the mechanisms that maintain Treg suppressive function within the tumor microenvironment (TME) is critical. Here, we identify an accumulation of N-acetyltransferase 10 (Nat10)-modified RNA, particularly in Nat10⁺ Foxp3⁺ Treg cells, in human non-small cell lung cancer (NSCLC). Genetic ablation of Nat10 in tumor-infiltrating (TI) Treg cells, or pharmacological inhibition of Nat10 expression, significantly reduces the PD-1⁺ Treg/CD8⁺ T cell ratio. These effects are accompanied by an increase in IFNγ⁺ Treg cells, a reduction in the immunosuppressive activity of Treg cells, and inhibition of tumor progression. Mechanistically, Nat10 promotes TI Treg cell infiltration and activation independently of its RNA-modifying function by directly interacting with Foxp3 and chromatin, shaping 3D genome architecture. Combined administration of anti-PD-1 antibodies and a Nat10 inhibitor further impairs TI Treg-mediated immunosuppression, leading to enhanced tumor control. Our findings demonstrate that Nat10 is a key regulator of TI Treg cell fragility and function, and that its inhibition may enhance the therapeutic efficacy of ICB.</description><dates><publication>2026/08/21</publication></dates><accession>GSE254341</accession><cross_references><GSM>GSM8038005</GSM><GSM>GSM8038004</GSM><GSM>GSM8038003</GSM><GSM>GSM8038022</GSM><GSM>GSM8038021</GSM><GSM>GSM8038020</GSM><GSM>GSM9092579</GSM><GSM>GSM9092578</GSM><GSM>GSM9092577</GSM><GSM>GSM8038009</GSM><GSM>GSM9092576</GSM><GSM>GSM8038008</GSM><GSM>GSM9092575</GSM><GSM>GSM8038007</GSM><GSM>GSM8038006</GSM><GSM>GSM9092583</GSM><GSM>GSM9092582</GSM><GSM>GSM9092581</GSM><GSM>GSM9092580</GSM><GSM>GSM8038016</GSM><GSM>GSM8038015</GSM><GSM>GSM8038014</GSM><GSM>GSM8038013</GSM><GSM>GSM8038012</GSM><GSM>GSM8038011</GSM><GSM>GSM8038010</GSM><GSM>GSM9872194</GSM><GSM>GSM9872193</GSM><GSM>GSM9872196</GSM><GSM>GSM9872195</GSM><GSM>GSM9872198</GSM><GSM>GSM9092586</GSM><GSM>GSM9872197</GSM><GSM>GSM8038019</GSM><GSM>GSM8038018</GSM><GSM>GSM9092585</GSM><GSM>GSM9092584</GSM><GSM>GSM9872199</GSM><GSM>GSM8038017</GSM><GSM>GSM9872192</GSM><GPL>24676</GPL><GPL>24247</GPL><GSE>254341</GSE><taxon> Mus musculus</taxon><taxon>Homo sapiens</taxon></cross_references></HashMap>